Evidence map›Paper›PMID 39488657›Full record

ArticleScientific reports2024

Engineering of self-assembled silver-peptide colloidal nanohybrids with enhanced biocompatibility and antibacterial activity.

Nyla Saeed, Atia Atiq, Farhat Rafiq, Iliyas Khan, Maria Atiq, Muhammad Saleem, Dalaver H Anjum, Zahid Usman, Manzar Abbas

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nyla SaeedInstitute of Physics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Atia AtiqDivision of Science and Technology, Department of Physics, University of Education, Lahore, Pakistan.
Farhat RafiqSchool of Biological Sciences, University of the Punjab, Lahore, Pakistan.
Iliyas KhanDepartment of Chemistry, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
Maria AtiqInstitute of Physics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan. maria.atiq@iub.edu.pk.
Muhammad SaleemSchool of Biological Sciences, University of the Punjab, Lahore, Pakistan.
Dalaver H AnjumDepartment of Physics, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
Zahid UsmanDivision of Science and Technology, Department of Physics, University of Education, Lahore, Pakistan.
Manzar AbbasDepartment of Chemistry, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, United Arab Emirates. manzar.abbas@ku.ac.ae.

Funding

Khalifa University of Science and Technology 8474000462
6 · The paper itself

Abstract

Several bacterial strains have developed resistance against commercial antibiotics, and interestingly, supramolecular nanomaterials have shown considerable advantages for antibacterial applications. However, the main challenges in adopting nanotechnology for antibacterial studies are random aggregation, compromised toxicity, multi-step preparation approaches, and unclear structure-function properties. Herein, we designed the amphiphilic tripeptide that acts as a reducing and capping agent for silver metal to form silver-peptide colloidal nanohybrids with the mild assistance of UV light (254 nm) through the photochemical reduction method. The nanohybrids are characterized by different spectroscopic and microscopic techniques, and non-covalent molecular interactions between metal and peptide building blocks confirm their central role in the formation of nanohybrids. The tripeptide is biocompatible and can reduce the toxicity of silver ions (Ag

Indexed as

Anti-Bacterial AgentsBiocompatible MaterialsColloidsSilverEscherichia coliHumansMetal NanoparticlesMicrobial Sensitivity TestsPeptidesAnti-Bacterial AgentsBiocompatible MaterialsColloidsPeptidesSilverAntibacterial activityColloidsNanohybridsPeptideReducing and capping agentSelf-assembly

Identifiers

PMID39488657
PMCPMC11531511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.